116-9e
Based on 2 publication(s) in Google Scholar
116-9e (MAL2-11B) is a Hsp70 co-chaperone DNAJA1 inhibitor. 116-9e inhibits Simian Virus 40 (SV40) replication and DNA synthesis. 116-9e inhibits tumor antigen (TAg)’s endogenous ATPase activity and the TAg-mediated activation of Hsp70.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.28%
- CAS. Nr.: 831217-43-7
- Formel: C31H32N2O5
- Molecular Weight:512.60
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) 116-9e
MoreAlle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SK-BR-3 | GI50 |
>50 μM
Compound: MAL2-11B
|
Antiproliferative activity against human SK-BR3 cells after 96 hrs by MTS assay
Antiproliferative activity against human SK-BR3 cells after 96 hrs by MTS assay
|
[PMID: 18164205] |
116-9e (MAL2-11B) inhibits TAg stimulation of Hsp70 with greater efficacy than MAL3-101, significantly reduces viral replication and DNA synthesis. MAL2-11B also inhibits the activity of the TAg ATPase domain[1].
?
116-9e (MAL2-11B; 15 μM; 5 days) significantly reduces the growth of BK virus in a human kidney cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 831217-43-7
-
Appearance Solid
-
Molecular Weight 512.60
-
Formel C31H32N2O5
-
Color White to yellow
-
SMILES
O=C(CCCCCN1C(C)=C(C(NC1=O)C2=CC=C(C=C2)C3=CC=CC=C3)C(OCC4=CC=CC=C4)=O)O
-
Synonyms
MAL2-11B
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
A kinase-independent Bcr-Abl function mediating an Hsp70-Bim protein-protein interaction in chronic myeloid leukemia. [Abstract]2025 Apr 16:143249. PMID: 40250683 -
J Virol
2025 Jun 5:e0050225. PMID: 40470959
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (195.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.88 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (563 KB)
- English - EN (563 KB)
- Français - FR (563 KB)
- Deutsch - DE (563 KB)
- Norwegian - NO (563 KB)
- Español - ES (563 KB)
- Swedish - SV (563 KB)
- Italian - IT (563 KB)
- Korean - KR (563 KB)
- Portuguese - PT (563 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Christine M Wright, et al. Inhibition of Simian Virus 40 replication by targeting the molecular chaperone function and ATPase activity of T antigen. Virus Res. 2009 Apr;141(1):71-80. [Content Brief]
[2]. Nitika, et al. Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance. Sci Rep. 2020 Aug 14;10(1):13831. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9508 mL | 9.7542 mL | 19.5084 mL | 48.7710 mL |
| 5 mM | 0.3902 mL | 1.9508 mL | 3.9017 mL | 9.7542 mL | |
| 10 mM | 0.1951 mL | 0.9754 mL | 1.9508 mL | 4.8771 mL | |
| 15 mM | 0.1301 mL | 0.6503 mL | 1.3006 mL | 3.2514 mL | |
| 20 mM | 0.0975 mL | 0.4877 mL | 0.9754 mL | 2.4385 mL | |
| 25 mM | 0.0780 mL | 0.3902 mL | 0.7803 mL | 1.9508 mL | |
| 30 mM | 0.0650 mL | 0.3251 mL | 0.6503 mL | 1.6257 mL | |
| 40 mM | 0.0488 mL | 0.2439 mL | 0.4877 mL | 1.2193 mL | |
| 50 mM | 0.0390 mL | 0.1951 mL | 0.3902 mL | 0.9754 mL | |
| 60 mM | 0.0325 mL | 0.1626 mL | 0.3251 mL | 0.8128 mL | |
| 80 mM | 0.0244 mL | 0.1219 mL | 0.2439 mL | 0.6096 mL | |
| 100 mM | 0.0195 mL | 0.0975 mL | 0.1951 mL | 0.4877 mL |